Chemical Component Summary

FormulaC23 H20 F3 N5 O2 S2
Molecular Weight519.56
Isomeric SMILESCC(C)(C)c1nc(c(s1)-c1ccnc(N)n1)-c1cccc(NS(=O)(=O)c2c(F)cccc2F)c1F

Chemical Details

Formal Charge0
Atom Count55
Chiral Atom Count0
Chiral Atomsn/a
Bond Count58
Aromatic Bond Count23
Leaving Atomsn/a

Drug Info: DrugBank

DrugBank IDDB08912 Different stereochemistry
DescriptionDabrafenib mesylate is a reversible ATP-competitive kinase inhibitor and targets the MAPK pathway. FDA approved on May 29, 2013.
  • Dabrafenib
  • GSK2118436a
SaltsDabrafenib Mesylate
Brand NamesTafinlar
Affected OrganismHumans and other mammals
IndicationDabrafenib is indicated for the treatment of patients with unresectable or metastatic melanoma with BRAF V600E mutation as detected by an FDA-approved test.
PharmacologyDabrafenib caused an inhibition of phosphorylated ERK. This indicates a decrease in cell proliferation. Furthermore, within 24 hours of administration, downstream mediators of the MAPK pathway were inhibited.
Mechanism of actionDabrafenib is an inhibitor of some mutated forms of BRAF kinases with in vitro IC50 values of 0.65, 0.5, and 1.84 nM for BRAF V600E, BRAF V600K, and BRAF V600D enzymes, respectively. Dabrafenib also inhibits wild-type BRAF and CRAF kinases with IC50 values of 3.2 and 5.0 nM, respectively, and other kinases such as SIK1, NEK11, and LIMK1 at higher concentrations. Some mutations in the BRAF gene, including those that result in BRAF V600E, can result in constitutively activated BRAF kinases that may stimulate tumor cell growth.
Route of administrationOral
  • Amines
  • Antineoplastic Agents
  • Antineoplastic and Immunomodulating Agents
  • Azoles
  • BCRP/ABCG2 Inhibitors
Drug Info/Drug Targets: DrugBank 3.0: a comprehensive resource for 'omics' research on drugs. Knox C, Law V, Jewison T, Liu P, Ly S, Frolkis A, Pon A, Banco K, Mak C, Neveu V, Djoumbou Y, Eisner R, Guo AC, Wishart DS. Nucleic Acids Res. 2011 Jan; 39 (Database issue):D1035-41. | PMID:21059682